{"id":52584,"date":"2023-01-05T16:02:59","date_gmt":"2023-01-05T15:02:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/applied-dna-announces-publication-of-peer-reviewed-journal-article-validating-potential-use-of-lineardna-as-a-new-class-of-dna-based-vaccines\/"},"modified":"2023-01-05T16:02:59","modified_gmt":"2023-01-05T15:02:59","slug":"applied-dna-announces-publication-of-peer-reviewed-journal-article-validating-potential-use-of-lineardna-as-a-new-class-of-dna-based-vaccines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/applied-dna-announces-publication-of-peer-reviewed-journal-article-validating-potential-use-of-lineardna-as-a-new-class-of-dna-based-vaccines\/","title":{"rendered":"Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA\u2122 as a New Class of DNA-Based Vaccines"},"content":{"rendered":"
\n

\n– Company Advances Lipid Nanoparticle (LNP)-based Delivery System to Potentially Broaden LinearDNA Platform Commercial Utility –<\/i>\n<\/p>\n

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN<\/a> #LinearDNA<\/a>—Applied DNA Sciences, Inc.<\/a> (NASDAQ: APDN) (the \u201cCompany\u201d), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy \u2013 Methods & Clinical Development<\/a>. The study, titled \u2018A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,\u2019 supports the further development of the Company\u2019s LinearDNA\u2122 platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA\u2122-based vaccines. An initial manuscript detailing the study\u2019s findings was published in preprint form on bioRxiv<\/a> in July 2022.\n<\/p>\n

<\/a><\/p>\n

\nThe study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines. Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses. The study was performed in conjunction with development partner EvviVax, S.R.L.\n<\/p>\n

\n\u201cThis peer-reviewed publication supports the innovative work we and our partners are conducting to advance linearDNA as a potential new class of human and veterinary therapeutics that combines the rapid design and manufacturing capabilities akin to mRNA therapies with the thermostability and relative manufacturing simplicity of linearDNA. Adding to already robust data supporting the potential of linearDNA in-hand, this study and others being conducted and planned make a compelling case for linearDNA as a next-generation, DNA-based vaccine platform, in addition to its utility in the manufacture of other nucleic acid-based therapies, such as mRNA and CAR T therapies,\u201d stated Dr. James A. Hayward, president and CEO of Applied DNA.\n<\/p>\n

\nConcurrently, the Company is working to optimize the delivery in vivo<\/i> of linearDNA to increase its ease of administration via LNPs that, if successful, would represent a significant turning point in increasing the commercial viability of linearDNA. The Company is currently progressing two LNP-related studies in parallel:\n<\/p>\n